Different expression of S100A8 in malignant and benign gallbladder diseases

Digestive Diseases and Sciences

Volumn 58, Issue 1, 2013, Pages 150-162

  Wang, Wei ^b   Ai, Kai Xing ^a   Yuan, Zhou ^a   Huang, Xin Yu ^a   Zhang, Hui Zhen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Bile; Gallbladder cancer; Proteomics; S100A8

Indexed keywords

CALGRANULIN A;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER INFILTRATION; CANCER TISSUE; CHRONIC CHOLECYSTITIS; FEMALE; GALLBLADDER ADENOMA; GALLBLADDER CANCER; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

ADENOMA; BILE; CALGRANULIN A; CHOLECYSTITIS; CHRONIC DISEASE; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873154142     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2307-0     Document Type: Article

References (36)

1. Pitt HA. Gallbladder cancer: what is an aggressive approach? Ann Surg. 2005;241:395-396.
2. Shukla HS. Gallbladder Cancer. J Surg Oncol. 2006;93:604-606.
3. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Population proteomics: the concept, attributes, and potential for cancer biomarker research. Mol Cell Proteom. 2006;5:1811-1818.
4. Simpson RJ, Dorow DS. Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol. 2001;19:40-48.
5. Chen CY, Tsai WL, Wu HC, et al. Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis. Clin Chim Acta. 2008;390:82-89.
6. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics. 2004;4:3276-3287.
7. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004;15:24-30.
8. Farina A, Dumonceau JM, Frossard JL, Hadengue A, Hochstrasser DF, Lescuyer P. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res. 2009;8:159-169.
9. Niu D, Feng H, Chen WN. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery. J Proteomics. 2010;73:1283-1290.
10. Wang JW, Peng SY, Li JT, et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett. 2009;281:71-81.
11. Bonney GK, Craven RA, Prased R, et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008;9:149-158.
12. Guerrier L, Claverol S, Finzi L, et al. Contribution of solid-phase hexapeptide ligand libraries to the repertoire of human bile proteins. J Chromatogr A. 2007;1176:192-205.
13. Kristiansen TZ, Bunkenborg J, Gronborg M, et al. A proteomic analysis of human bile. Mol Cell Proteom. 2004;3:715-728.
14. Liu Y, Wu J, Yan G, et al. Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry. Proteome Sci. 2010;8:2.
15. Ishihama Y, Oda Y, Tabata T, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteom. 2005;4:1265-1272.
16. Zhou H, Chen B, Li RX, et al. Large-scale identification of human biliary proteins from a cholesterol stone patient using a proteomic approach. Rapid Commun Mass Spectrom. 2005;19:3569-3578.
17. Lankisch TO, Metzger J, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011;53:875-884.
18. Sheikh AA, Vimalachandran D, Thompson CC, et al. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics. 2007;7:1929-1940.
19. Washiro M, Ohtsuka M, Kimura F, et al. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target. J Cancer Res Clin Oncol. 2008;134:793-801.
20. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 2002;3:235-243.
21. Farina A, Dumonceau JM, Delhaye M, Frossard JL, Hadengue A, Hochstrasser DF, Lescuyer P. A step further in the analysis of human bile proteome. J Proteome Res. Epub. 02/11/2011.
22. Farina A, Dumonceau JM, Lescuyer P. Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev Proteom. 2009;6:285-301.
23. Lo WY, Lai CC, Hua CH, et al. S100A8 is identified as a biomarker of HPV18-infected oral squamous cell carcinomas by suppression subtraction hybridization, clinical proteomic analysis, and immunohistochemistry staining. J Proteome Res. 2007;6:2143-2151.
24. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72:1622-1631.
25. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003;60:569-580.
26. Lundy FT, Chalk R, Lamey PJ, Shaw C, Linden GJ. Identification of MRP-8 (calgranulin A) as a major responsive protein in chronic periodontitis. J Pathol. 2000;192:540-544.
27. de Seny D, Fillet M, Ribbens C, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem. 2008;54:1066-1075.
28. Rafii S, Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol. 2006;8:1321-1323.
29. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lungmetastasis. Nat Cell Biol. 2006;8:1369-1375.
30. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62:6823-6826.
31. Kim HJ, Kang HJ, Lee H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res. 2009;8:1368-1379.
32. Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005;11:5146-5152.
33. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005;46:256-269.
34. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37.
35. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
36. Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology. 2009;55:218-229.